Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'

Ann Rheum Dis. 2023 May;82(5):e111. doi: 10.1136/annrheumdis-2021-220044. Epub 2021 Feb 16.

Maria De Santis^#¹, Antonio Voza^#², Victor Savevski³, Salvatore Badalamenti⁴, Maurizio Cecconi^{5

6}, Alberto Mantovani^{6

7

8}, Carlo Selmi^{9

6}

¹ Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy.
² Emergency Department, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy.
³ Artificial Intelligence Research, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy.
⁴ Nephrology, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy.
⁵ Anesthesiology and Intensive Care, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
⁶ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
⁷ Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
⁸ The William Harvey Research Institute, Queen Mary University of London, London, UK.
⁹ Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Lombardia, Italy carlo.selmi@hunimed.eu.

^# Contributed equally.

No abstract available

Keywords: Covid-19; cytokines; glucocorticoids.

Publication types